In the BioHarmony Drug Report Database

"Preview" Icon

Sonidegib

Odomzo (sonidegib) is a small molecule pharmaceutical. Sonidegib was first approved as Odomzo on 2015-07-24. It is used to treat skin neoplasms in the USA. It has been approved in Europe to treat basal cell carcinoma. The pharmaceutical is active against smoothened homolog. Odomzo’s patents are valid until 2029-09-15 (FDA).

 

Trade Name

 

Odomzo
 

Common Name

 

sonidegib
 

ChEMBL ID

 

CHEMBL2105737
 

Indication

 

basal cell carcinoma, skin neoplasms
 

Drug Class

 

Hedgehog signaling inhibitors

Image (chem structure or protein)

Sonidegib structure rendering